Premium Lumateperone API in Pakistan: Reliable Raw Material Supply for Pharmaceutical Formulators

Product Name: Lumateperone / Lumateperone Tosylate (Active Pharmaceutical Ingredient)

Supplier / Distributor: Morgan

Therapeutic Category: Second-Generation Atypical Antipsychotic

Indications: Schizophrenia, Bipolar Depression (Bipolar I and Bipolar II Disorder)

Compliance Notice: This technical data page is strictly for B2B pharmaceutical manufacturers, contract manufacturing organizations (CMOs), and analytical laboratories. The Lumateperone distributed by Morgan is a highly purified Active Pharmaceutical Ingredient (API) intended exclusively for commercial formulation and laboratory R&D. It is not a finished drug product.

About Morgan: Morgan Chemicals (Pvt.) Ltd. is a pharmaceutical raw material trading and distribution company. We source APIs from DRAP-registered and internationally certified manufacturers and supply exclusively to licensed pharmaceutical companies, CMOs, and research facilities. We do not manufacture APIs or sell finished medicines.

Product Overview and Mechanism of Action

Lumateperone is a highly advanced, small-molecule Active Pharmaceutical Ingredient (API). In the field of central nervous system (CNS) pharmacology, it is classified as a next-generation atypical antipsychotic. For pharmaceutical manufacturers focused on expanding their neuropsychiatric portfolios, this API represents a significant breakthrough in managing complex mood and psychotic disorders with a highly favorable tolerability profile.

What distinguishes Lumateperone from legacy antipsychotics is its unique and multifaceted mechanism of action, which simultaneously modulates dopaminergic, serotonergic, and glutamatergic neurotransmission. At the cellular level, the API exhibits a binding affinity for the serotonin 5-HT2A receptor that is approximately 60 times greater than its affinity for the dopamine D2 receptor.

Its mechanism functions across several key neural pathways:

• Serotonergic System: It acts as a potent antagonist at 5-HT2A receptors and exhibits moderate inhibition of the serotonin transporter (SERT), effectively targeting depressive and negative symptoms.
• Dopaminergic System: Uniquely, it functions as a partial agonist at presynaptic D2 autoreceptors (reducing excess dopamine release) and as an antagonist at postsynaptic D2 receptors.
• Glutamatergic System: It indirectly enhances NMDA and AMPA receptor signaling via a dopamine D1 receptor-dependent pathway, a mechanism critical for improving cognitive deficits in schizophrenia.

Crucially, Lumateperone avoids significant off-target interactions with muscarinic or histaminergic receptors, minimizing the metabolic syndromes and weight gain historically associated with atypical antipsychotics. In commercial manufacturing, this active ingredient is typically formulated into 42 mg oral solid capsules (equivalent to 60 mg of Lumateperone Tosylate).

Sourcing Lumateperone in Pakistan: Morgan’s Supply Network

Developing and commercializing advanced CNS formulations requires a highly resilient and traceable raw material pipeline. Procuring specialty psychiatric APIs for local commercial manufacturing frequently involves navigating extended lead times, stringent customs bottlenecks, and highly complex regulatory compliance. Sourcing Lumateperone Pakistan through Morgan’s localized distribution network mitigates these complex supply chain risks.

Morgan sources commercial-scale and pilot-scale quantities from global manufacturing partners operating in strict adherence to ICH Q7 Good Manufacturing Practice (GMP) guidelines. Partnering with Morgan as your primary supply vendor secures several operational provisions for your manufacturing facility:

• DRAP Submission Assistance: Morgan coordinates with DRAP-registered API manufacturers to obtain and forward the necessary compliance documentation on your behalf. This includes the open part of the Drug Master File (DMF), comprehensive impurity profiles, and accelerated stability data to strictly support your Drug Regulatory Authority of Pakistan (DRAP) dossier submissions.
• Supply Chain Stability: Our localized API inventory management eliminates international transit variables. Whether your facility requires a standard pilot batch or is scaling up a high-volume Lumateperone api Pakistan procurement order, we help ensure that your commercial batch schedules are met without costly line stoppages.
• Batch-to-Batch Uniformity: Every shipment coordinated by Morgan includes a detailed Certificate of Analysis (CoA) issued by the original manufacturer. We ensure our supplied batches maintain consistent chemical purity, controlled moisture limits, and a precise particle size distribution (PSD) for predictable behavior during compounding and capsule filling processes.

Technical Specifications for QA & R&D

The Lumateperone API (supplied predominantly as the tosylate salt) undergoes exacting analytical testing at the source to meet current international pharmacopeial standards.

• Chemical Name: 1-(4-fluorophenyl)-4-[(10R,15S)-4-methyl-1,4,12-triazatetracyclo[7.6.1.05,16.010,15]hexadeca-5,7,9(16)-trien-12-yl]butan-1-one;4-methylbenzenesulfonic acid (Tosylate Salt)
• CAS Number: 1187020-80-9 (Tosylate) / 313368-91-1 (Free base)
• Appearance: White to off-white or light yellowish crystalline solid powder
• Molecular Formula: C24H28FN3O · C7H8O3S
• Molecular Weight: 565.7 g/mol (Tosylate salt)
• Assay / Purity (HPLC): ≥ 99.0%
• Solubility Profile: Soluble in organic solvents such as methanol and dimethyl sulfoxide (DMSO); sparingly soluble in aqueous buffers. Detailed solubility parameters are documented in the technical data sheet to assist your analytical R&D teams with dissolution profiling.

Manufacturing and Handling Guidelines for Formulators

Lumateperone is a highly potent, centrally acting pharmacological compound. Facilities processing this API must enforce strict occupational exposure limits (OEL) to protect personnel on the manufacturing floor.

• Storage Conditions: Store the raw API powder in securely closed, light-resistant containers. Maintain climate-controlled conditions as specified by the batch protocol (typically refrigerated at 2-8°C or controlled room temperature, strictly protected from excessive heat and humidity) to prevent degradation and maintain structural integrity.
• Occupational Safety: Personnel handling the pure API powder must follow advanced industrial containment protocols. Processing requires appropriate Personal Protective Equipment (PPE), including P3/N95 industrial dust masks or powered air-purifying respirators (PAPR), chemical-resistant nitrile gloves, and full protective facility garments. Dispensing, micronization, milling, and blending stages must be executed within localized exhaust ventilation systems or dedicated negative-pressure containment isolators to prevent the inhalation of airborne particulates and facility cross-contamination.

Distributor Disclaimer: Morgan Chemicals is a pharmaceutical raw material trading and distribution company. This API is sourced from DRAP-registered, GMP-certified manufacturing partners. Morgan Chemicals does not manufacture APIs, does not hold DRAP manufacturing registration, and does not sell finished medicines. This product is supplied exclusively to licensed pharmaceutical companies, CMOs, and research facilities in Pakistan — not for individual or consumer sale.